glp 1 and intracranial hypertension The effect of glucagon-like peptide-1 agonists on ocular parameters in idiopathic patients: a retrospective study GLP-1 drugs may provide benefit
Description
The decrease in BMI was also comparatively substantial compared to dulaglutide, semaglutide, and placebo [22,63]
These drugs are part of the -tide family, indicating their peptide structure
Second, GLP-1 therapies modestly reduce systolic blood pressure
and C.Z
Among those who switched therapies, more than 8 out of 10 (81.8%) patients switched to AOM semaglutide
